阿糖胞苷与阿糖腺苷均为临床常用的药物，使用过程中易被误用。本文结合热点事件对临床药物阿糖胞苷与阿糖腺苷的来源，临床用途等做一叙述。继而结合我国医疗管理相关的法律法规，进一步分析导致临床用药差错的成因、用药差错的后果以及预防措施等。本文旨在减少临床用药差错，进一步提高我国临床用药水平。

Medication errors are an important problem in pediatrics. Cytarabine and vidarabine are commonly used in pediatrics. But people are apt to confuse the two drugs. In this paper, we analyze the source and clinical use of cytarabine and vidarabine, and all causes of medication errors and possible preventive measures, as well as the legal responsibility of medication errors in Chinese laws and regulations. In short, we propose some suggestions to reduce medication errors, improve medication levels in our country.

探讨单磷酸阿糖腺苷治疗儿童传染性单核细胞增多症(IM)的效果。方法:165例确诊为IM患儿,按照治疗方案分为阿糖腺苷组92例和更昔洛韦组73例,阿糖腺苷组静脉滴注单磷酸阿糖腺苷注射液10 mg/kg,1次/天,总疗程10~14 d;更昔洛韦组静脉滴注更昔洛韦注射液10 mg/kg,2次/天,7 d后改为5 mg/kg,1次/天,总疗程10~14 d。观察2组急性期热程、咽峡炎改善时间、肝脾淋巴结回缩时间、异型淋巴细胞数恢复至正常时间并比较2组疗效。结果:2组在急性期热程、咽峡炎的改善、肝脾淋巴结回缩及异型淋巴细胞计数恢复至正常时间差异均无统计学意义(P0.05);2组总有效率差异亦无统计学意义(P0.05)。结论:单磷酸阿糖腺苷可取得与更昔洛韦治疗儿童IM相同的效果。

Objective:To explore the effects of vidarabine monophosphate in the treatment of infectious mononucleosis ( IM ) in children. Methods:One hundred and sixty-five children with IM were divided into vidarabine group 92 cases and ganciclovir group 73 cases according to their treatment protocol. The vidarabine group and ganciclovir group were treated with 10 mg/kg of vidarabine through intravenous drip once a day for 10 to 14 days and 10 mg/kg of ganciclovir through intravenous drip once 12 hours for 7 days, then 5 mg/kg once a day for 3 to 7 days, respectively. The fever course of acute phase, isthmopyra improvement time, hepatic and splenic lymph node retraction time and atypical lymphocyte recovery time in two groups were observed. The curative effects of two groups were analysed. Results:The differences of the fever course of acute phase, isthmopyra improvement time, hepatic and splenic lymph node retraction time and atypical lymphocyte recovery time between two groups were not statisti

目的探讨单磷酸阿糖腺苷联合薄芝糖肽治疗带状疱疹的临床治疗效果及应用价值。方法选择我院治疗的带状疱疹患者92例，随机分为观察组和对照组，对照组采用泛昔洛韦联合薄芝糖肽、维生素B1、维生素B12治疗，观察组在对照组治疗的基础上给予单磷酸阿糖腺苷进行治疗，观察两组的临床治疗效果。结果观察组总有效率高于对照组，经统计学分析比较，差异有统计学意义（P〈0.05）.观察组患者水疱干涸结痂、疼痛缓解、疼痛消失时间、后遗神经痛发生率均优于对照组，经统计学分析比较，差异有统计学意义（P〈0．05）。结论采用单磷酸阿糖腺苷联合泛昔洛韦、薄芝糖肽治疗带状疱疹起效快，疗效显著，降低后遗神经痛发生率，值得在临床大力推广使用。

Objective To discuss the clinical treatment effect and application value of vidarabine monophosphate combined with bozhi glycopeptide in the treatment of patients with herpes zoster. Methods Ninety-two patients with herpes zoster who received treatment in our hospital were chose and randomly divided into the observation group and the control group. The patients in the control group were treated with famciclovir combined with Bozhi glycopeptide and vitamin B1, vitamin B12, while the patients in the observation group were treated with vidarabine monophosphate on the basis of the control group. The clinical therapeutic effect of two groups was observed. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). The blister drying and scabbing, pain relieving, pain disappearing time and incidence of neuralgia of patients in the observation group were better than those in the control group, the

目的考察人免疫球蛋白联合阿糖腺苷和甲强龙治疗EB病毒感染的临床疗效。方法将100例EB病毒感染患者随机分为研究组和对照组,每组各50例。对照组给予阿糖腺苷和甲强龙治疗,研究组给予人免疫球蛋白联合单磷酸阿糖腺苷和甲强龙治疗。比较两组的病毒转阴率和治疗前后的症状总积分。结果研究组病毒转阴率为82.0%,对照组为50.0%,两组存在统计学差异（P〈0.01）;治疗前研究组和对照组的症状总积分分别为（12.3±9.4）和（10.9±7.0）分,两组无统计学差异（P〉0.05）,治疗后研究组和对照组的症状总积分分别为（3.9±3.3）和（6.1±4.8）分,两组存在统计学差异（P〈0.05）。结论人免疫球蛋白联合阿糖腺苷和甲强龙治疗EB病毒感染安全、有效,具有临床应用价值。

Objective To observe the effects of immunoglobulin treatment combined with Vidarabine(Ara-A)and Sou-Medrol (Sou-M)on EB virus infection. Methods Total 100 patients with EB infection were selected and divided into two groups,i. e. ,control group and study group,50 ones in each group. For the control group,vidarabine monophosphate and prednisolone were administered, while human immunoglobulin with Are-A and prednisolone were administered together for the study group. The negative transformation rate of virus and the total symptom scores were compared before and after the treatment of the two groups and between both groups. Results The negative transformation rate of virus was 82. 0% in the study group and was 50. 0% in the control group. The different between the two groups was significant(P 0. 05);but after the treatment,the total symptoms scores were 3. 9 ± 3. 3 and 6. 1 ± 4. 8,respectively,and there was a significant difference between both groups( P < 0. 05). Conclusion T

目的：观察热毒宁联合利巴韦林与热毒宁联合阿糖腺苷两种方案治疗小儿疱疹性咽峡炎的疗效，探讨经济、有效的治疗小儿疱疹性咽峡炎的方法。方法将符合诊断标准的疱疹性咽峡炎患儿随机分为两组，各42例。一组热毒宁联合利巴韦林，另一组热毒宁联合阿糖腺苷，疗程3~5 d，并根据病情给予对症支持治疗，比较两组临床疗效及不良反应。结果两组在退热、疱疹消失时间等方面，无显著性差异，两组总有效率分别为95.2%和97.6%。结论热毒宁联合利巴韦林与热毒宁联合阿糖腺苷两种方案治疗小儿疱疹性咽峡炎疗效均等，利巴韦林组更经济实惠。

Objective:To observe the curative ef ect of Reduning combined with ribavirin and Reduning injection and vidarabine two schemes in the treatment of ribavirin,another group of Reduning combined with adenosine,3~5 dinfantile herpangina,methods of treatment,children with herpangina economy ef ectively. Methods:children with herpangina randomly divided into 2 groups according to the diagnostic criteria,42 cases in each. A group of Reduning injection andays treatment according to the il ness,and give symptomatic and supportive treatment,compared 2 groups of clinical curative ef ect and adverse reaction. Results: the two groups in terms of antipyretic,bleb disappear time,there was no significant dif erence between the two groups,the total ef ective rate were 95.2% and 97.6%. Conclusion: Equal ef ect of Reduning combined with ribavirin and Reduning injection and vidarabine two schemes in treating infantile herpangina,ribavirin group more af ordable.